The potential move to rescind authorization of Pfizer's vaccine could leave some kids in the U.S. with no available shots ...

Novavax raised its full-year adjusted revenue forecast on Wednesday, betting on the strength of vaccine supply partnerships, including with Serum Institute of India and Japan's Takeda , sending its ...

Novavax raised its full-year adjusted revenue forecast on Wednesday, banking on higher sales tied to its vaccine supply ...

In this Feb. 26, 2022 file photo a kidney dish with syringes containing the Novavax COVID-19 vaccine sits in a refrigerator ready for use at a vaccination center in Prisdorf, Germany, Feb. 26, 2022.

Lots of people are hearing about Novavax, the fourth COVID vaccine option in the U.S., for the first time, but it’s been authorized for use as a primary vaccine series since early 2022.

The Novavax vaccine would be authorized for use in adults only in two doses. The company submitted a request, which the FDA is considering, to provide the same vaccine as a booster dose.

Novavax’s recent application for licensing its Covid-19 vaccine in Australia, Canada, and the UK hasn’t gained much traction in the US media. This is odd, given that the vaccine could not only ...

Novavax, a small biotech company in Maryland, garnered attention June 18 when it announced its vaccine candidate is more than 90% effective overall and 100% effective at preventing moderate to ...

Novavax, one of five COVID vaccine-makers to receive large federal grants, says its shots are more than 90% effective against infection.

Novavax asked the Food and Drug Administration to authorize its COVID-19 vaccine for adults in late-January and after long delays, the FDA is expected to decide within weeks whether to authorize ...

Vaccine maker Novavax said Monday its COVID-19 shot was highly effective against the disease and also protected against variants in a large study in the U.S. and Mexico, potentially offering the ...